Systematic identification and assessment of therapeutic targets for breast cancer based on genome-wide RNA interference transcriptomes

Genes

Volumn 8, Issue 3, 2017, Pages

  Liu, Yang ^a   Yin, Xiaoyao ^b   Zhong, Jing ^c   Guan, Naiyang ^b   Luo, Zhigang ^b   Min, Lishan ^c   Yao, Xing ^c   Bo, Xiaochen ^d   Dai, Licheng ^c   Bai, Hui ^d,e  

^a BEIJING 302 HOSPITAL   (China)

^b NATIONAL UNIVERSITY OF DEFENSE TECHNOLOGY   (China)

^c HUZHOU CENTRAL HOSPITAL   (China)

^d BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^e No 451 Hospital of PLA   (China)

Author keywords

Breast cancer; Cancer Gene Census; DNA methylation; Drug target; Gene set enrichment analysis; Library of integrated network based cellular signatures

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRANSCRIPTOME;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GENE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; COMPUTER ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE SILENCING; GENE TARGETING; GENETIC ANALYSIS; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN TISSUE; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MCF-7 CELL LINE; MOLECULARLY TARGETED THERAPY; RNA INTERFERENCE; RNA SEQUENCE; TRIPLE NEGATIVE BREAST CANCER; VALIDATION STUDY;

EID: 85014610093     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes8030086     Document Type: Article

References (66)

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 2016, 66, 7–30. [CrossRef] [PubMed]
2. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015, 65, 87–108. [CrossRef] [PubMed]
3. Kalimutho, M.; Parsons, K.; Mittal, D.; Lopez, J.A.; Srihari, S.; Khanna, K.K. Targeted therapies for triple-negative breast cancer: Combating a stubborn disease. Trends Pharmacol. Sci. 2015, 36, 822–846. [CrossRef] [PubMed]
4. Foulkes, W.D.; Smith, I.E.; Reis-Filho, J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010, 363, 1938–1948. [CrossRef] [PubMed]
5. Carey, L.; Winer, E.; Viale, G.; Cameron, D.; Gianni, L. Triple-negative breast cancer: Disease entity or title of convenience? Nat. Rev. Clin. Oncol. 2010, 7, 683–692. [CrossRef] [PubMed]
6. Perou, C.M.; Sorlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; et al. Molecular portraits of human breast tumours. Nature 2000, 406, 747–752. [CrossRef] [PubMed]
7. Liedtke, C.; Mazouni, C.; Hess, K.R.; Andre, F.; Tordai, A.; Mejia, J.A.; Symmans, W.F.; Gonzalez-Angulo, A.M.; Hennessy, B.; Green, M.; et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008, 26, 1275–1281. [CrossRef] [PubMed]
8. Carey, L.A.; Dees, E.C.; Sawyer, L.; Gatti, L.; Moore, D.T.; Collichio, F.; Ollila, D.W.; Sartor, C.I.; Graham, M.L.; Perou, C.M. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007, 13, 2329–2334. [CrossRef] [PubMed]
9. von Minckwitz, G.; Untch, M.; Blohmer, J.U.; Costa, S.D.; Eidtmann, H.; Fasching, P.A.; Gerber, B.; Eiermann, W.; Hilfrich, J.; Huober, J.; et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol. 2012, 30, 1796–1804. [CrossRef] [PubMed]
10. Xu, H.; Eirew, P.; Mullaly, S.C.; Aparicio, S. The omics of triple-negative breast cancers. Clin. Chem. 2014, 60, 122–133. [CrossRef] [PubMed]
11. Speers, C.; Tsimelzon, A.; Sexton, K.; Herrick, A.M.; Gutierrez, C.; Culhane, A.; Quackenbush, J.; Hilsenbeck, S.; Chang, J.; Brown, P. Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin. Cancer Res. 2009, 15, 6327–6340. [CrossRef] [PubMed]
12. Hartman, Z.C.; Poage, G.M.; den Hollander, P.; Tsimelzon, A.; Hill, J.; Panupinthu, N.; Zhang, Y.; Mazumdar, A.; Hilsenbeck, S.G.; Mills, G.B.; et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 2013, 73, 3470–3480. [CrossRef] [PubMed]
13. Al-Ejeh, F.; Simpson, P.T.; Sanus, J.M.; Klein, K.; Kalimutho, M.; Shi, W.; Miranda, M.; Kutasovic, J.; Raghavendra, A.; Madore, J.; et al. Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. Oncogenesis 2014, 3, e100. [CrossRef] [PubMed]
14. Lawrence, R.T.; Perez, E.M.; Hernandez, D.; Miller, C.P.; Haas, K.M.; Irie, H.Y.; Lee, S.I.; Blau, C.A.; Villen, J. The proteomic landscape of triple-negative breast cancer. Cell Rep. 2015, 11, 630–644. [CrossRef] [PubMed]
15. Osmanbeyoglu, H.U.; Pelossof, R.; Bromberg, J.F.; Leslie, C.S. Linking signaling pathways to transcriptional programs in breast cancer. Genome Res. 2014, 24, 1869–1880. [CrossRef] [PubMed]
16. Song, H.; Hedayati, M.; Hobbs, R.F.; Shao, C.; Bruchertseifer, F.; Morgenstern, A.; Deweese, T.L.; Sgouros, G. Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-egfr antibody. Mol. Cancer Ther. 2013, 12, 2043–2054. [CrossRef] [PubMed]
17. Ueno, N.T.; Zhang, D. Targeting egfr in triple negative breast cancer. J. Cancer 2011, 2, 324–328. [CrossRef] [PubMed]
18. Dent, S.F. The role of vegf in triple-negative breast cancer: Where do we go from here? Ann. Oncol. 2009, 20, 1615–1617. [CrossRef] [PubMed]
19. Furth, P.A. Stat signaling in different breast cancer sub-types. Mol. Cell. Endocrinol. 2014, 382, 612–615. [CrossRef] [PubMed]
20. Gordon, V.; Banerji, S. Molecular pathways: Pi3k pathway targets in triple-negative breast cancers. Clin. Cancer Res. 2013, 19, 3738–3744. [CrossRef] [PubMed]
21. Yunokawa, M.; Koizumi, F.; Kitamura, Y.; Katanasaka, Y.; Okamoto, N.; Kodaira, M.; Yonemori, K.; Shimizu, C.; Ando, M.; Masutomi, K.; et al. Efficacy of everolimus, a novel mtor inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci. 2012, 103, 1665–1671. [CrossRef] [PubMed]
22. Chin, Y.R.; Yoshida, T.; Marusyk, A.; Beck, A.H.; Polyak, K.; Toker, A. Targeting akt3 signaling in triple-negative breast cancer. Cancer Res. 2014, 74, 964–973. [CrossRef] [PubMed]
23. Montero, J.C.; Esparis-Ogando, A.; Re-Louhau, M.F.; Seoane, S.; Abad, M.; Calero, R.; Ocana, A.; Pandiella, A. Active kinase profiling, genetic and pharmacological data define mtor as an important common target in triple-negative breast cancer. Oncogene 2014, 33, 148–156. [CrossRef] [PubMed]
24. Murai, J.; Huang, S.Y.; Das, B.B.; Renaud, A.; Zhang, Y.; Doroshow, J.H.; Ji, J.; Takeda, S.; Pommier, Y. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012, 72, 5588–5599. [CrossRef] [PubMed]
25. Johnson, N.; Johnson, S.F.; Yao, W.; Li, Y.C.; Choi, Y.E.; Bernhardy, A.J.; Wang, Y.; Capelletti, M.; Sarosiek, K.A.; Moreau, L.A.; et al. Stabilization of mutant brca1 protein confers parp inhibitor and platinum resistance. Proc. Natl. Acad. Sci. USA 2013, 110, 17041–17046. [CrossRef] [PubMed]
26. Crown, J.; O. Shaughnessy, J.; Gullo, G. Emerging targeted therapies in triple-negative breast cancer. Ann. Oncol. 2012, 23, vi56–vi65. [CrossRef] [PubMed]
27. Jamdade, V.S.; Sethi, N.; Mundhe, N.A.; Kumar, P.; Lahkar, M.; Sinha, N. Therapeutic targets of triple-negative breast cancer: A review. Br. J. Pharmacol. 2015, 172, 4228–4237. [CrossRef] [PubMed]
28. Saha, P.; Nanda, R. Concepts and targets in triple-negative breast cancer: Recent results and clinical implications. Ther. Adv. Med. Oncol. 2016, 8, 351–359. [CrossRef] [PubMed]
29. Lin, A.; Li, C.; Xing, Z.; Hu, Q.; Liang, K.; Han, L.; Wang, C.; Hawke, D.H.; Wang, S.; Zhang, Y.; et al. The link-a lncrna activates normoxic hif1alpha signalling in triple-negative breast cancer. Nat. Cell Biol. 2016, 18, 213–224. [CrossRef] [PubMed]
30. Lehmann, B.D.; Pietenpol, J.A.; Tan, A.R. Triple-negative breast cancer: Molecular subtypes and new targets for therapy. Am. Soc. Clin. Oncol. Educ. Book 2015. [CrossRef] [PubMed]
31. Wu, S.Y.; Lopez-Berestein, G.; Calin, G.A.; Sood, A.K. RNAi therapies: Drugging the undruggable. Sci. Transl. Med. 2014. [CrossRef] [PubMed]
32. Mansoori, B.; Sandoghchian Shotorbani, S.; Baradaran, B. RNA interference and its role in cancer therapy. Adv. Pharm. Bull. 2014, 4, 313–321. [PubMed]
33. Abdelrahim, M.; Safe, S.; Baker, C.; Abudayyeh, A. RNAi and cancer: Implications and applications. J. RNAi Gene Silencing 2006, 2, 136–145. [PubMed]
34. Trevino, V.; Falciani, F.; Barrera-Saldana, H.A. DNA microarrays: A powerful genomic tool for biomedical and clinical research. Mol. Med. 2007, 13, 527–541. [CrossRef] [PubMed]
35. Peck, D.; Crawford, E.D.; Ross, K.N.; Stegmaier, K.; Golub, T.R.; Lamb, J. A method for high-throughput gene expression signature analysis. Genome Biol. 2006. [CrossRef] [PubMed]
36. Zhu, J.; Sanborn, J.Z.; Benz, S.; Szeto, C.; Hsu, F.; Kuhn, R.M.; Karolchik, D.; Archie, J.; Lenburg, M.E.; Esserman, L.J.; et al. The ucsc cancer genomics browser. Nat. Methods 2009, 6, 239–240. [CrossRef] [PubMed]
37. Parker, J.S.; Mullins, M.; Cheang, M.C.; Leung, S.; Voduc, D.; Vickery, T.; Davies, S.; Fauron, C.; He, X.; Hu, Z.; et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 2009, 27, 1160–1167. [CrossRef] [PubMed]
38. Futreal, P.A.; Coin, L.; Marshall, M.; Down, T.; Hubbard, T.; Wooster, R.; Rahman, N.; Stratton, M.R. A census of human cancer genes. Nat. Rev. Cancer 2004, 4, 177–183. [CrossRef] [PubMed]
39. Wishart, D.S.; Knox, C.; Guo, A.C.; Shrivastava, S.; Hassanali, M.; Stothard, P.; Chang, Z.; Woolsey, J. Drugbank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006, 34, D668–D672. [CrossRef] [PubMed]
40. Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.; Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545–15550. [CrossRef] [PubMed]
41. Ritchie, M.E.; Phipson, B.; Wu, D.; Hu, Y.; Law, C.W.; Shi, W.; Smyth, G.K. Limma powers differential expression analyses for rna-sequencing and microarray studies. Nucleic Acids Res. 2015. [CrossRef] [PubMed]
42. Kaplan, E.L.; Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958, 53, 457–481. [CrossRef]
43. Huang da, W.; Sherman, B.T.; Lempicki, R.A. Systematic and integrative analysis of large gene lists using david bioinformatics resources. Nat. Protoc. 2009, 4, 44–57. [CrossRef] [PubMed]
44. Mi, H.; Poudel, S.; Muruganujan, A.; Casagrande, J.T.; Thomas, P.D. Panther version 10: Expanded protein families and functions, and analysis tools. Nucleic Acids Res. 2016, 44, D336–D342. [CrossRef] [PubMed]
45. Sorlie, T.; Tibshirani, R.; Parker, J.; Hastie, T.; Marron, J.S.; Nobel, A.; Deng, S.; Johnsen, H.; Pesich, R.; Geisler, S.; et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 2003, 100, 8418–8423. [CrossRef] [PubMed]
46. Klijn, C.; Durinck, S.; Stawiski, E.W.; Haverty, P.M.; Jiang, Z.; Liu, H.; Degenhardt, J.; Mayba, O.; Gnad, F.; Liu, J.; et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 2015, 33, 306–312. [CrossRef] [PubMed]
47. Holliday, D.L.; Speirs, V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011, 13, 215. [CrossRef] [PubMed]
48. Chapman, K.B.; Prendes, M.J.; Sternberg, H.; Kidd, J.L.; Funk, W.D.; Wagner, J.; West, M.D. COL10A1 expression is elevated in diverse solid tumor types and is associated with tumor vasculature. Future Oncol. 2012, 8, 1031–1040. [CrossRef] [PubMed]
49. Cheng, C.W.; Yu, J.C.; Wang, H.W.; Huang, C.S.; Shieh, J.C.; Fu, Y.P.; Chang, C.W.; Wu, P.E.; Shen, C.Y. The clinical implications of MMP-11 and CK-20 expression in human breast cancer. Clin. Chim. Acta 2010, 411, 234–241. [CrossRef] [PubMed]
50. Cappello, P.; Blaser, H.; Gorrini, C.; Lin, D.C.; Elia, A.J.; Wakeham, A.; Haider, S.; Boutros, P.C.; Mason, J.M.; Miller, N.A.; et al. Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells. Oncogene 2014, 33, 2375–2384. [CrossRef] [PubMed]
51. Mulvihill, M.M.; Benjamin, D.I.; Ji, X.; Le Scolan, E.; Louie, S.M.; Shieh, A.; Green, M.; Narasimhalu, T.; Morris, P.J.; Luo, K.; et al. Metabolic profiling reveals PAFAH1B3 as a critical driver of breast cancer pathogenicity. Chem. Biol. 2014, 21, 831–840. [CrossRef] [PubMed]
52. Wang, H.; Lu, C.; Li, Q.; Xie, J.; Chen, T.; Tan, Y.; Wu, C.; Jiang, J. The role of kif4a in doxorubicin-induced apoptosis in breast cancer cells. Mol. Cells 2014, 37, 812–818. [CrossRef] [PubMed]
53. Mikeska, T.; Craig, J.M. DNA methylation biomarkers: Cancer and beyond. Genes 2014, 5, 821–864. [CrossRef] [PubMed]
54. Widschwendter, M.; Jones, P.A. DNA methylation and breast carcinogenesis. Oncogene 2002, 21, 5462–5482. [CrossRef] [PubMed]
55. Pakneshan, P.; Szyf, M.; Farias-Eisner, R.; Rabbani, S.A. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J. Biol. Chem. 2004, 279, 31735–31744. [CrossRef] [PubMed]
56. Du, P.; Zhang, X.; Huang, C.C.; Jafari, N.; Kibbe, W.A.; Hou, L.; Lin, S.M. Comparison of beta-value and m-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 2010, 11, 587. [CrossRef] [PubMed]
57. Gendler, S.J. MUC1, the renaissance molecule. J. Mammary Gland Biol. Neoplasia 2001, 6, 339–353. [CrossRef] [PubMed]
58. Nath, S.; Mukherjee, P. Muc1: A multifaceted oncoprotein with a key role in cancer progression. Trends Mol. Med. 2014, 20, 332–342. [CrossRef] [PubMed]
59. Apostolopoulos, V.; Pietersz, G.A.; McKenzie, I.F. Muc1 and breast cancer. Curr. Opin. Mol. Ther. 1999, 1, 98–103. [PubMed]
60. Kufe, D.W. MUC1-C oncoprotein as a target in breast cancer: Activation of signaling pathways and therapeutic approaches. Oncogene 2013, 32, 1073–1081. [CrossRef] [PubMed]
61. Chen, X.; Iliopoulos, D.; Zhang, Q.; Tang, Q.; Greenblatt, M.B.; Hatziapostolou, M.; Lim, E.; Tam, W.L.; Ni, M.; Chen, Y.; et al. Xbp1 promotes triple-negative breast cancer by controlling the hif1alpha pathway. Nature 2014, 508, 103–107. [CrossRef] [PubMed]
62. Yeo, E.J.; Cassetta, L.; Qian, B.Z.; Lewkowich, I.; Li, J.F.; Stefater, J.A.; Smith, A.N.; Wiechmann, L.S.; Wang, Y.; Pollard, J.W.; et al. Myeloid WNT7B mediates the angiogenic switch and metastasis in breast cancer. Cancer Res. 2014, 74, 2962–2973. [CrossRef] [PubMed]
63. Rangel, L.B.; Agarwal, R.; Sherman-Baust, C.A.; Mello-Coelho, V.; Pizer, E.S.; Ji, H.; Taub, D.D.; Morin, P.J. Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers. Cancer Biol. Ther. 2004, 3, 1021–1027. [CrossRef] [PubMed]
64. Bourguignon, L.Y.; Zhu, H.; Shao, L.; Chen, Y.W. Ankyrin-Tiam1 interaction promotes Rac1 signaling and metastatic breast tumor cell invasion and migration. J. Cell. Biol. 2000, 150, 177–191. [CrossRef] [PubMed]
65. Sizemore, G.M.; Sizemore, S.T.; Seachrist, D.D.; Keri, R.A. GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2). J. Biol. Chem. 2014, 289, 24102–24113. [CrossRef] [PubMed]
66. Masters, J.R. Human cancer cell lines: Fact and fantasy. Nature Rev. Mol. Cell Biol. 2000, 1, 233–236. [CrossRef] [PubMed]